Search Results - "Merlo, Christian"

Association Between Respiratory Tract Methicillin-Resistant Staphylococcus aureus and Survival in Cystic Fibrosis by Dasenbrook, Elliott C, Checkley, William, Merlo, Christian A, Konstan, Michael W, Lechtzin, Noah, Boyle, Michael P

“…CONTEXT The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in the respiratory tract of individuals with cystic fibrosis (CF) has increased…”
Get full text

Host responses to mucosal biofilms in the lung and gut by Domingue, Jada C., Drewes, Julia L., Merlo, Christian A., Housseau, Franck, Sears, Cynthia L.

“…The impact of the human microbiome on health and disease is of utmost importance and has been studied intensively in recent years. Microbes promote immune…”
Get full text

Evaluation of both exonic and intronic variants for effects on RNA splicing allows for accurate assessment of the effectiveness of precision therapies by Joynt, Anya T, Evans, Taylor A, Pellicore, Matthew J, Davis-Marcisak, Emily F, Aksit, Melis A, Eastman, Alice C, Patel, Shivani U, Paul, Kathleen C, Osorio, Derek L, Bowling, Alyssa D, Cotton, Calvin U, Raraigh, Karen S, West, Natalie E, Merlo, Christian A, Cutting, Garry R, Sharma, Neeraj

“…Elucidating the functional consequence of molecular defects underlying genetic diseases enables appropriate design of therapeutic options. Treatment of cystic…”
Get full text

An epistaxis severity score for hereditary hemorrhagic telangiectasia by Hoag, Jeffrey B., Terry, Peter, Mitchell, Sally, Reh, Douglas, Merlo, Christian A.

“…Objectives/Hypothesis: Hereditary hemorrhagic telangiectasia (HHT)‐related epistaxis leads to alterations in social functioning and quality of life. Although…”
Get full text

Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis by Merlo, Christian A, Thorat, Teja, DerSarkissian, Maral, McGarry, Lisa J, Nguyen, Catherine, Gu, Yuqian M, Healy, Joe, Rubin, Jaime L, Brookhart, M Alan

“…Ivacaftor (IVA) has been shown to improve lung function and other clinical outcomes in people with cystic fibrosis (CF). A decade of real-world IVA…”
Get more information

Persistent Methicillin-resistant Staphylococcus aureus and Rate of FEV1 Decline in Cystic Fibrosis by Dasenbrook, Elliott C, Merlo, Christian A, Diener-West, Marie, Lechtzin, Noah, Boyle, Michael P

“…The prevalence in cystic fibrosis (CF) of respiratory cultures with methicillin-resistant Staphylococcus aureus (MRSA) has dramatically increased over the last…”
Get full text

Race-Specific Interpretation of Spirometry: Impact on the Lung Allocation Score by Brems, J Henry, Balasubramanian, Aparna, Psoter, Kevin J, Shah, Pali, Bush, Errol L, Merlo, Christian A, McCormack, Meredith C

“…Interpretation of spirometry using race-specific reference equations may contribute to health disparities via underestimation of the degree of lung function…”
Get full text

Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis by Merlo, Christian A, McGarry, Lisa J, Thorat, Teja, Nguyen, Catherine, DerSarkissian, Maral, Muthukumar, Aruna, Healy, Joe, Brookhart, M Alan, Rubin, Jaime L

“…Ivacaftor (IVA) improves lung function and other extrapulmonary outcomes in people with cystic fibrosis (CF). However, the effect of initiating IVA at earlier…”
Get more information

Early United States experience with lung donation after circulatory death using thoracoabdominal normothermic regional perfusion by Zhou, Alice L., Ruck, Jessica M., Casillan, Alfred J., Larson, Emily L., Shou, Benjamin L., Karius, Alexander K., Ha, Jinny S., Shah, Pali D., Merlo, Christian A., Bush, Errol L.

“…Thoracoabdominal normothermic regional perfusion (TA-NRP) has recently begun being utilized in the United States for recovery of cardiothoracic allografts from…”
Get full text

An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor by Jennings, Mark T, Dezube, Rebecca, Paranjape, Shruti, West, Natalie E, Hong, Gina, Braun, Andrew, Grant, Jonathan, Merlo, Christian A, Lechtzin, Noah

“…In July 2015, the U.S. Food and Drug Administration approved lumacaftor/ivacaftor for use in patients with cystic fibrosis (CF). This drug targets the primary…”
Get full text

Acute Kidney Injury Increases Mortality After Lung Transplantation by George, Timothy J., MD, Arnaoutakis, George J., MD, Beaty, Claude A., MD, Pipeling, Matthew R., MD, Merlo, Christian A., MD, MPH, Conte, John V., MD, Shah, Ashish S., MD

“…Background Acute kidney injury requiring renal replacement therapy (RRT) is associated with increased mortality after cardiac surgery. Studies examining the…”
Get full text

Selection of Candidates for Lung Transplantation and Controversial Issues by Orens, Jonathan B, Merlo, Christian A

“…Lung transplantation is a widely accepted treatment to manage the advanced stages of many lung diseases that have failed to respond to all other therapeutic…”
Get more information

Sarcopenia of the Psoas Muscles Is Associated With Poor Outcomes Following Lung Transplantation by Hsu, Joshua, Krishnan, Aravind, Lin, Cheng T., Shah, Pali D., Broderick, Stephen R., Higgins, Robert S.D., Merlo, Christian A., Bush, Errol L.

“…Sarcopenia, a known component of frailty, defined by diminished cross-sectional area of the psoas muscles, is associated with poor outcomes after a range of…”
Get full text

Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients by Iasella, Carlo J, Hannan, Stefanie J, Lyons, Emily J, Lieber, Sophia C, Das, Antu, Dimitrov, Dimiter, Li, Wei, Saul, Melissa, Popescu, Iulia, Koshy, Ritchie, Burke, Robin, Lape, Braidon, Brown, Mark J, Chen, Xiaoping, Sembrat, John C, Devonshire, Kaitlyn, Kitsios, Georgios D, Konstantinidis, Ioannis, Snyder, Mark E, Chen, Bill B, Merlo, Christian A, Hager, David N, Kiss, Joseph E, Yazer, Mark H, Wells, Alan H, Morris, Alison, McVerry, Bryan J, McMahon, Deborah K, Triulzi, Darrell J, McDyer, John F

“…COVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the…”
Get full text

Outcomes of Lung Transplant Candidates Aged ≥70 Years During the Lung Allocation Score Era by Zhou, Alice L., Karius, Alexander K., Ruck, Jessica M., Shou, Benjamin L., Larson, Emily L., Casillan, Alfred J., Ha, Jinny S., Shah, Pali D., Merlo, Christian A., Bush, Errol L.

“…With the increasing age of lung transplant candidates, we studied waitlist and posttransplantation outcomes of candidates ≥70 years during the Lung Allocation…”
Get full text

To decline or not to decline: Consequences of decision-making regarding lung offers from donors with hepatitis C by Ruck, Jessica M, Bowring, Mary G, Durand, Christine M, Ha, Jinny S, Massie, Allan B, Segev, Dorry L, Merlo, Christian A, Bush, Errol L

“…Lung transplants from donors with hepatitis C (HCV D+) have excellent outcomes, but these organs continue to be declined. We evaluated whether (1) being listed…”
Get full text

National utilization, trends, and lung transplant outcomes of static versus portable ex vivo lung perfusion platforms by Zhou, Alice L., Ruck, Jessica M., Casillan, Alfred J., Larson, Emily L., Shou, Benjamin L., Ha, Jinny S., Shah, Pali D., Merlo, Christian A., Bush, Errol L.

“…This study compared utilization and outcomes of the 2 widely utilized ex vivo lung perfusion (EVLP) platforms in the United States: a static platform and a…”
Get full text

Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial by Whitehead, Kevin J, Sautter, Nathan B, McWilliams, Justin P, Chakinala, Murali M, Merlo, Christian A, Johnson, Maribeth H, James, Melissa, Everett, Eric M, Clancy, Marianne S, Faughnan, Marie E, Oh, S. Paul, Olitsky, Scott E, Pyeritz, Reed E, Gossage, James R

“…IMPORTANCE: Epistaxis is a major factor negatively affecting quality of life in patients with hereditary hemorrhagic telangiectasia (HHT; also known as…”
Get full text

Uptake and 1-year outcomes of lung transplantation for COVID-19 by Ruck, Jessica M, Zhou, Alice L, Florissi, Isabella, Ha, Jinny S, Shah, Pali D, Massie, Allan B, Segev, Dorry L, Merlo, Christian A, Bush, Errol L

“…End-stage lung disease from severe COVID-19 infection is an increasingly common indication for lung transplantation (LT), but there are limited data on…”
Get full text

Impact of dual thoracic recovery from circulatory death donors on heart and lung transplant outcomes by Zhou, Alice L., Rizaldi, Alexandra A., Ruck, Jessica M., Akbar, Armaan F., Kalra, Andrew, Casillan, Alfred J., Ha, Jinny S., Merlo, Christian A., Kilic, Ahmet, Bush, Errol L.

“…Concomitant heart and lung recovery can result in increased operative complexity, ischemic time, and competition for resources and anatomic territory. Dual…”
Get full text